Ethyl cellulose (EC) microcapsules containing Salbutamol sulphate (SS) were prepared through emulsion-solvent evaporation technique. Microcapsules were compressed and in-vitro release profiles were studied from both microcapsules and their compressed matrix tablets. Different amounts of drug were added in order to obtain various drugs to polymer ratios and it was found that the size of microcapsules reduced with the increase in core loading. In the preparation of formulations, Tween 80 was used as an emulsifying or dispersing agent and light liquid paraffin (LLP) was used as oil phase. The in-vitro release of EC microcapsules was studied in distilled water at 37º ± 0.5°C. A biphasic release behavior of SS from microcapsules was observed. In case of microcapsules, an immediate release was observed but for their compressed tablet form, initially a burst effect and then slow release were observed which was extended for 8 hours. In order to further investigate the type of drug release mechanism, the dissolution data were plotted according to the different kinetic models. In-vitro dissolution studies showed that zero-order and square-root of time (Higuchi model) release characteristics were exhibited.
Introduction
Salbutamol sulphate is a potent β-2 adrenoceptor stimulant which is used for the treatment of reversible airways obstruction. It is readily absorbed from the gastrointestinal tract when administered orally. Its biological half life is about 4 to 6 hours. In recent years, the number of patients with chronic diseases is increasing day by day. Taking a lot of medicines simultaneously, this can lead to reduced patient compliance. This problem is serious for such drugs with short biological half lives because they must be taken more frequently. In this situation, it is necessary to develop drugs for a longer period. One method to solve such problems is to develop a dosage form capable of releasing the drug gradually. In this regard, microencapsulation has been used as one of the tools to formulate controlled drug delivery systems (Yamada et al., 2001) .
Ethyl cellulose (EC) is generally considered as a nontoxic, biocompatible and non-biodegradable polymer.
These characteristics are the reasons of its extensive selection for development of oral dosage forms, especially sustained release formulations. This is the reason why EC is extensively used for the development of oral multi-unit dosage forms (i.e. microcapsules). EC coated microcapsules have also demonstrated their capability to absorb pressure and therefore save the coating from fracture during tablet manufacturing process. This process involves the conversion of multi-unit system into a single unit dosage form by compression, which disintegrates slowly into sub-units when exposed to dissolution process (Rowe et al., 2003) .
Alteration of any independent variable factor like emulsifier type, rate of organic solvent evaporation, core loading, rate of stirring, core solubility etc may affect the final microcapsule characteristics and release kinetics (Fong et al., 1986; Tice et al., 1985; Spenlehauer et al., 1986; Wakiyama et al., 1982 a,b; Jalil et al., 1990) . The purposes of the present study were: a) to prepare and Correspondence to: Jakir Ahmed Chowdhury; Tel: +880-2-7219747; Fax: +880-2-8615583; E-mail: jakirdu96@gmail.com characterize SS microcapsules using EC as wall material by the emulsion-solvent evaporation technique; b) to determine the effect of the polymer to drug ratio on invitro dissolution study; c) to investigate how microcapsules and their compressed matrix tablet form affect the drug release; d) to fit the data to various postulated drug release kinetic models.
Material and Methods
Materials and reagents: Salbutamol sulphate (Incepta Pharmaceuticals Ltd.), Ethyl cellulose (Ethocel 20 cps, Colorcon, USA), Light liquid paraffin (MERCK, Germany), Tween 80 (MERCK, Germany), acetone (MERCK, Germany), n-hexane (MERCK, Germany) were used in this study from the indicated sources.
Preparation of ethyl cellulose microcapsule: EC microcapsules containing SS were prepared using the emulsification and organic solvent evaporation technique (Jalil et al., 1989) . Acetone was used as polymer solvent, light liquid paraffin (LLP) as the microcapsulating vehicle and n-hexane as the decanter of paraffin oil. To prepare microcapsules with various drug to polymer ratios such as 1 : 1, 1 : 2 and 1 : 3, an amount of 1.8 g of polymer (EC) was weighed and either 1.8, 0.9 or 0.6 g of SS was added, respectively. The drug to polymer ratio was varied keeping the amount of polymer and solvent constant in all cases and decreasing the amount of drug used. An amount of 1.8 g of polymer (EC) was dissolved in 15 ml of acetone. Depending on the desired ratio, weighed amounts of SS were dispersed in this solution and stirred for 20 min by a high speed stirrer (Heidolph, England). The dispersion was poured into 100 ml of LLP containing 1.3 % Tween 80 and stirred for 3 hours at 1500 rpm at room temperature. After 3 hours of stirring, the solvent for EC was completely evaporated and hard as well as spherical shaped microcapsules were found. Prepared microcapsules were then washed twice with 100 ml of n-hexane and consequently were separated by filtration. A vacuum dryer (VEEGO, India) was used to dry to obtain free-flowing microcapsules.
Evaluation of microcapsules prepared with ethyl cellulose
Drug content determination: At room temperature, stock solutions of SS (0 to 18 µg/ml) in distilled water were prepared and the absorbance was measured by UV-VIS Spectrophotometer (UV mini-1240, SHIMADZU CORP., Kyoto, Japan) at 276nm. A linear line was obtained while absorbance values were plotted against concentrations (R 2 = 0.9993).
Drug (SS) loaded EC microcapsules of each batch were finely powdered in a glass mortar. A clear solution of the powder was made using distilled water after proper sonication by a sonicator (POWER SONIC 505, HWASHIN TECHNOLOGY CO., Seoul, Korea). The solutions of the microcapsule samples were subjected to ultrasonication in order to achieve the complete breakage of the microcapsule wall and to release the total drug content. Therefore, the samples of solution were filtered through 0.45 µm filter and analyzed spectrophotometrically for drug content (Gohel et al., 1998; Florey 1990 ).
The drug loading (%) was calculated using the following equation:
The encapsulation efficiency (%) was determined by the following equation:
In vitro dissolution study: Microcapsules of a particular size range were separated with the help of a sieve set (Endecotts Limited, England) for dissolution study. The USP paddle method was used to determine release of SS from the microcapsules which was carried out in a USP XXX apparatus Type-2 (Paddle Apparatus) in 900 ml distilled water of 37º ± 0.5 ºC at a rotational speed of 50 rpm. Dissolution samples were withdrawn at appropriate intervals up to 8 hours and then filtered through 0.45 µm filters. The drug content was determined spectrophotometrically at λ max = 276 nm in the filtrate either directly or after appropriate dilution with the dissolution media. The dissolution study for each batch was performed in triplicate.
Kinetic models: All data obtained from in-vitro release studies were fitted to various kinetic equations to find out the mechanism of drug release from the EC microcapsule. In this study, the kinetic models (1) zeroorder kinetics (Eq. 1) and (2) 
Where, Q is the amount of drug release in time t, k 0 , and k H are rate constant of zero order and Higuchi rate equations respectively. Determining the correlation coefficient assessed fitness of the data into various kinetic models. The rate constants, for respective models were also calculated from slopes.
Results and Discussion
Encapsulation efficiency: The drug to polymer ratio varied, maintaining the amount of polymer and solvent constant in all cases and decreasing the amount of drug used. As the drug to polymer ratio increased the microcapsules' mean size decreased (Table 1 ). The reduction in microcapsule size with increase in drug to polymer ratio may be due to a decrease in the viscosity of the internal phase as a result of a decrease in the concentration of solids in polymer solution.
In vitro release kinetics: The effect of variation in drug to polymer ratio on drug release was studied on SS microcapsules and their compressed matrix tablet forms in a dissolution medium of distilled water. The release profile of all microcapsule formulations was characterized by a typical initial burst effect due to SS release from the surface of the microcapsules. The rapid release attributed to leaching of drug through pores and channels after water imbibition. For the preparation of EC microcapsules containing SS, different drug to polymer ratio such as 1:1 (SM50), 1:2 (SM33) and 1:3 (SM25) were taken and found that increase in polymer concentration resulted in a decrease of drugs release rate (Figure 1) . Initially, the compressed forms of the three respective formulations (SMC50, SMC33 and SMC25) showed burst release but after one and half hours a sustained release up to 8 hours was achieved. In case of compressed matrix tablet forms of the microcapsules, a decrease of drugs release was also found with increased in polymer concentration (Figure 2 and Figure 3 ). The releases of SS microcapsule were found to be higher as compared to their respective compressed matrix tablet forms' release. The release data obtained were fitted into two release kinetic models and release kinetics table (Table 2 ) was prepared.
Conclusion
EC Microcapsules containing SS were successfully prepared by W/O emulsion solvent-evaporation technique. It could be concluded that different drug to polymer ratio in the formulations influenced the variation observed in drug loading as well as entrapment efficiency, mean particle size and the drug release behavior. The results of this study may put forward the prospective application of ethyl cellulose microcapsules as a suitable sustainedrelease drug delivery system. Hence, a single unit sustained release oral dosage form of ethyl cellulose microcapsules containing salbutamol sulphate is promising to formulate twice daily dose for respective patients.
